W0 2011/000721 A1 I||||||||||||||||||||||||||||||||||||||||||||||||||||||||| - Questel

More documents

Recommendations

Info

and with variable quantities of compound 12. Fig. 9 shows the results of the trans-infection of CD4+ T lymphocytes by HIV-1 strain 89,6 (dual tropic) after exposure to BTHP1/DC-SIGN+ cells preincubated with the virus and with variable quantities of compound 12. Fig. 10 shows the results of the trans- infection of CD4+ T lymphocytes by HIV BaI after exposure to BTHP1/DC- SIGN+ cells preincubated with the virus and with variable quantities (10 and 100 μM) of compounds 12, analogue tetravalent mannose (Man4), analogue tetravalent pseudo-dimannose (12a), boltorn third generation dendrimers mannosylated (G3Man32) and ps-diMannosylated (G3PS-di24) which is a third generation dendrimer based on 2,2'-bis(methoxyol)propanoic acid (bis- MPA). Fig. 11 shows a preferred compound of the invention 12 (SARA 133). Fig. 12 shows some 2,2'-bis(methoxyol)propanoic acid (bis-MPA) based dendrimers, while Fig. 13 shows poly(amidoamine) (PAMAM) based dendrons and dendrimers within the present invention. Fig. 14 shows the dose/response for the infection of cervical explants with HIV-1 BaL in the presence of increasing amounts of dendron 12. Data represent p24 levels 3 and 7 days after infection and are presented as the average of 5 independent experiments using cervical explants from separate donors. DETAILED DESCRIPTION OF THE INVENTION As for the first object of the invention, there are provided compounds of general formula (I): [X-Y] -Z (I) wherein X is a saccharidic or pseudosaccharidic unit, Y is a linker, Z is a scaffold and a z is the functionality of the scaffold Z , i.e. the number of X unit it can bind, which is comprised between 1 and 150. In particular, according to the present invention, X is a M'-D-M group, wherein:
M' is a saccharidic or pseudo-saccharidic non-reducing end unit, that is to say a sugar residue or a sugar residue having one or more modified ring substituents, respectively, which is not capable of reducing the oxidizing agents such as Tollens reagents (AgO), of formula D is of formula wherein R 2 may be hydroxyl (-OH), alkoxy (-0-R'), wherein R' is a C1-C8 linear or branched, saturated or unsaturated alkyl chain and is preferably a methoxy group (-OCH 3 ), or R 2 is -N-R 3 2, wherein each R 3 may be independently H, a C1-C8 linear or branched, saturated or unsaturated alkyl chain, optionally substituted with an A group, wherein the A group may be a C3-C6 saturated or partially unsaturated cyclic- or heterocyclic ring or a C5-C6 aromatic or heteroaromatic ring, which cyclic or heterocyclic, aromatic or heteroaromatic ring may be optionally substituted at any available position with one or more of hydroxyl (-OH), C1-C8 linear or branched, saturated or unsaturated alkyl chain, C1-C8 linear or branched, saturated or unsaturated alkoxy carbon chain,
Page 1 and 2: (12) INTERNATIONAL APPLICATION PUBL
Page 3 and 4: mannose disaccharide (Manα1-2Man),
Page 5: It is a forth object of the inventi
Page 9 and 10: wherein Q and n are above disclosed
Page 12 and 13: wherein R is as above disclosed,
Page 14 and 15: may be made of gold, silver, Fe 2 O
Page 16 and 17: Within the compound of formula (I)
Page 18 and 19: wherein R and R 2 are as above repo
Page 20 and 21: through the Y linker and n is 1 to
Page 22 and 23: and (12a) 12b. As per a third aspec
Page 24 and 25: H wherein Q is selected from — N
Page 26 and 27: According to a second object of the
Page 28 and 29: wherein aj is 32 and J is a third g
Page 30 and 31: eactions requiring anhydrous condit
Page 32 and 33: To a solution of the silylmannopyra
Page 34 and 35: 3H, CH 3 CO), 1.99 (s, 3H, CH 3 CO)
Page 36 and 37: To a solution of the compound 9 (12
Page 38 and 39: (C2 D ), 70.36 (C6 M ), 70.01 (C6 M
Page 40 and 41: EXAMPLE 2 Synthesis of compound 12a
Page 42 and 43: 13 C-NMR (100 MHz, D2 O) δ (ppm):
Page 44 and 45: (the R5 tropic laboratory-adapted s
Page 46 and 47: derived from 1 (see above); G3Man32
Page 48 and 49: CLAIMS: 1 A compound of general for
Page 50: OCH 3 ), hydroxymethyl (-CH 2 OH),
Page 53 and 54: alkyl chain, C1-C8 linear or branch
Page 55 and 56: 7 . A compound having the general f
Page 57 and 58:
H wherein Q is selected from — N
Page 59:
or methyl substituted 1,3-thiazole;
Page 62 and 63:
wherein R 2 may be hydroxyl (-0H),
Page 64 and 65:
12. A compound according to claim 1
Page 66:
or methyl substituted 1,3-thiazole;
Page 82 and 83:
INTERNATIONAL SEARCH REPORT C(Conti
show all

W0 2011/000721 A1 I||||||||||||||||||||||||||||||||||||||||||||||||||||||||| - Questel

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?